ABSTRACT
Neurodegenerative diseases like Parkinson’s disease (PD) and Alzheimer’s disease (AD) are increasing alarmingly among the aging population of the entire world. Therefore, early disease prevention and/or treatment is highly desirable, but requires early diagnosis. Intrinsic to the neurodegenerative process of PD is nigrostriatal dopaminergic neuronal loss. Hence, a primary goal of PD research is to develop treatments to slow down the progressive nigrostriatal dopaminergic neurodegeneration and to reduce the functional decline of patients.
